Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OMER Wedbush Reiterates Outperform On Omeros Following Positive OMS721 Ex Vivo Results http://www.smarteranalyst.com/2014/11/20/wedbush-reiterates-outperform-on-omeros-following-positive-oms721-ex-vivo-results/
$GALE We Believe Galena's Stock Is Attractive, Says MLV; Raises PT To $5 http://www.smarteranalyst.com/2014/11/20/we-believe-galenas-stock-is-attractive-says-mlv-raises-pt-to-5/
$GALE We Believe Galena's Stock Is Attractive, Says MLV; Raises PT To $5 http://www.smarteranalyst.com/2014/11/20/we-believe-galenas-stock-is-attractive-says-mlv-raises-pt-to-5/
$INO Maxim Maintains Buy On Inovio Pharmaceuticals As It Adds Another Immunotherapy Product http://www.smarteranalyst.com/2014/11/20/maxim-maintains-buy-on-inovio-pharmaceuticals-as-another-immunotherapy-product-added-its-growing-cancer-rd-pipeline/
$SGYP Cantor Raises Synergy Pharmaceuticals Price Target Following Positive Phase 2 OIC Data For SP-333 http://www.smarteranalyst.com/2014/11/20/cantor-raises-synergy-pharmaceuticals-positive-phase-2-oic-data-for-sp-333/
$APRI Roth Capital Reiterates Buy On Apricus Biosciences Following 3Q14 Results http://www.smarteranalyst.com/2014/11/20/roth-capital-reiterates-buy-on-apricus-biosciences-following-3q14-results/
$MDT Oppenheimer Raises Medtronic Price Target Following Fiscal 2Q15 Earnings http://www.smarteranalyst.com/2014/11/19/oppenheimer-raises-medtronic-price-target-following-fiscal-2q15-earnings/
$IMUC Maxim Maintains Buy On ImmunoCellular Following SNO Data Review http://www.smarteranalyst.com/2014/11/19/maxim-maintains-buy-on-immunocellular-following-sno-data-review/
$MELA H.C. Wainwright Reiterates Buy On Mela Sciences As It Names New President And CEO http://www.smarteranalyst.com/2014/11/19/h-c-wainwright-reiterates-buy-on-mela-sciences-as-it-names-new-president-and-ceo/
$RMTI Rockwell, Unlike Dendreon Or Vivus, Has Far Greater To Fall, Says Brean Capital; Reiterates Sell http://www.smarteranalyst.com/2014/11/19/rockwell-unlike-dendreon-or-vivus-has-far-greater-to-fall-says-brean-capital-reiterates-sell/
$WFM What Drove the Recent Comp Acceleration at WFM? Oppenheimer's Rupesh Parikh Answers http://www.smarteranalyst.com/2014/11/19/what-drove-the-recent-comp-acceleration-at-wfm-oppenheimers-rupesh-parikh-answers/
$SRPT Roth Capital Remains Bullish On Sarepta Therapeutics, $22 PT http://www.smarteranalyst.com/2014/11/19/roth-capital-remains-bullish-on-sarepta-therapeutics-22-pt/
$SRPT Roth Capital Remains Bullish On Sarepta Therapeutics, $22 PT http://www.smarteranalyst.com/2014/11/19/roth-capital-remains-bullish-on-sarepta-therapeutics-22-pt/
$NBS H.C. Wainwright Comments On Neostem Following AMR-001 Data Release http://www.smarteranalyst.com/2014/11/19/h-c-wainwright-comments-on-neostem-following-amr-001-data-release/
$NBS H.C. Wainwright Comments On Neostem Following AMR-001 Data Release http://www.smarteranalyst.com/2014/11/19/h-c-wainwright-comments-on-neostem-following-amr-001-data-release/
$HAL $BHI The Agreement Between Halliburton And Baker Hughes Should Create LT Value, Says Deutsche Bank http://www.smarteranalyst.com/2014/11/18/the-agreement-between-halliburton-and-baker-hughes-should-create-lt-value-says-deutsche-bank/
$HAL $BHI The Agreement Between Halliburton And Baker Hughes Should Create LT Value, Says Deutsche Bank http://www.smarteranalyst.com/2014/11/18/the-agreement-between-halliburton-and-baker-hughes-should-create-lt-value-says-deutsche-bank/
RXi Pharmaceuticals Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/11/18/rxi-pharmaceuticals-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$NBS Maxim Remains Positive On Neostem Following PreSERVE AMI Phase 2 Results http://www.smarteranalyst.com/2014/11/18/maxim-remains-positive-on-neostem-following-preserve-ami-phase-2-results/
$NBS Maxim Remains Positive On Neostem Following PreSERVE AMI Phase 2 Results http://www.smarteranalyst.com/2014/11/18/maxim-remains-positive-on-neostem-following-preserve-ami-phase-2-results/
$KERX H.C. Wainwright Reiterates Buy On Keryx Biopharmaceuticals As Several KOLs Chime In http://www.smarteranalyst.com/2014/11/18/h-c-wainwright-reiterates-buy-on-keryx-biopharmaceuticals-as-several-kols-chime-in/
$NBS MLV Reduces Neostem Price Target As NBS10 Shows A Mortality Benefit But May Require Further Study http://www.smarteranalyst.com/2014/11/18/mlv-maintains-buy-on-neostem-shares-sees-176-upside-for-the-stock/
$NBS MLV Reduces Neostem Price Target As NBS10 Shows A Mortality Benefit But May Require Further Study http://www.smarteranalyst.com/2014/11/18/mlv-maintains-buy-on-neostem-shares-sees-176-upside-for-the-stock/
$THLD Cantor Fitzgerald Reaffirms Buy On Threshold Pharmaceuticals Following Strong GBM Data http://www.smarteranalyst.com/2014/11/18/cantor-fitzgerald-reaffirms-buy-on-threshold-pharmaceuticals-following-strong-gbm-data/
$SNSS Cantor Fitzgerald Maintains Hold On Sunesis Pharma, Sees 6% Downside For The Stock http://www.smarteranalyst.com/2014/11/18/cantor-fitzgerald-maintains-hold-on-sunesis-pharma-sees-6-downside-for-the-stock/
$SNSS Cantor Fitzgerald Maintains Hold On Sunesis Pharma, Sees 6% Downside For The Stock http://www.smarteranalyst.com/2014/11/18/cantor-fitzgerald-maintains-hold-on-sunesis-pharma-sees-6-downside-for-the-stock/
$SGYP Synergy Pharmaceuticals: Dilution Painful But Pipeline Is Advancing, Says Roth Capital http://www.smarteranalyst.com/2014/11/18/synergy-pharmaceuticals-dilution-painful-but-pipeline-is-advancing-says-roth-capital/
$HIMX Oppenheimer Downgrades Himax To Perform As Mobile Handset Market Is Expected To Be Volatile Next Year http://www.smarteranalyst.com/2014/11/18/oppenheimer-downgrades-himax-to-perform-as-mobile-handset-market-is-expected-to-be-volatile-next-year/
$KERX Brean Capital Reiterates Buy on Keryx Biopharmaceuticals Following Key Opinion Leader Forum http://www.smarteranalyst.com/2014/11/18/brean-capital-reiterates-buy-on-keryx-biopharmaceuticals-following-key-opinion-leader-forum/
$AAPL Oppenheimer Raises Apple Price Target On Near Term Market Share Gain Opportunities http://www.smarteranalyst.com/2014/11/18/oppenheimer-raises-apple-price-target-on-near-term-market-share-gain-opportunities/
$AAPL Oppenheimer Raises Apple Price Target On Near Term Market Share Gain Opportunities http://www.smarteranalyst.com/2014/11/18/oppenheimer-raises-apple-price-target-on-near-term-market-share-gain-opportunities/
$URBN Oppenheimer Cuts Urban Outfitters Price Target Following Earnings http://www.smarteranalyst.com/2014/11/18/oppenheimer-cuts-urban-outfitters-price-target-following-earnings/
$URBN Oppenheimer Cuts Urban Outfitters Price Target Following Earnings http://www.smarteranalyst.com/2014/11/18/oppenheimer-cuts-urban-outfitters-price-target-following-earnings/
$IMUC Maxim Reiterates Buy On ImmunoCellular As ICT107 Phase 2 Data Continues To Show Benefit http://www.smarteranalyst.com/2014/11/17/maxim-reiterates-buy-on-immunocellular-as-ict107-phase-2-data-continues-to-show-benefit/
$ISR Maxim Maintains Buy On IsoRay Following Fiscal 1Q:15 Results http://www.smarteranalyst.com/2014/11/17/maxim-maintains-buy-on-isoray-following-fiscal-1q15-results/
$CLDX Roth Capital Raises Celldex Therapeutics Price Target As Rindopepimut Delivered A Strong Showing At SNO http://www.smarteranalyst.com/2014/11/17/roth-capital-raises-celldex-therapeutics-price-target-as-rindopepimut-delivered-a-strong-showing-at-sno/
$CLDX Roth Capital Raises Celldex Therapeutics Price Target As Rindopepimut Delivered A Strong Showing At SNO http://www.smarteranalyst.com/2014/11/17/roth-capital-raises-celldex-therapeutics-price-target-as-rindopepimut-delivered-a-strong-showing-at-sno/
$SCTY Roth Capital Reiterates Buy On SolarCity Following Investor Meetings http://www.smarteranalyst.com/2014/11/17/roth-capital-reiterates-buy-on-solarcity-following-investor-meetings/
$KERX Maxim Reiterates Buy On Keryx Following OLE 48-Week Data for Ferric Citrate http://www.smarteranalyst.com/2014/11/17/maxim-reiterates-buy-on-keryx-following-ole-48-week-data-for-ferric-citrate/
$MPET Roth Capital Reduces Magellan Petroleum Price Target In Light Of Q1:15 Update http://www.smarteranalyst.com/2014/11/17/roth-capital-reduces-magellan-petroleum-price-target-in-light-of-q115-update/